Jorge Burgos
Internal Medicine · Las Vegas, NVNPI 1639275969
Payments from drug & device makers
Across 157 payments — averaging $41.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Biohaven Pharmaceuticals, Inc.$1K
- Novo Nordisk$580
- Boston Scientific$487
- Lilly USA, LLC$426
- Abbott$402
- plus $1K from 14 others
What the payments were for
- Consulting fees$1,20018%
- Food & beverage$5,23381%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,991 |
| Biohaven Pharmaceuticals, Inc. | 7 | $1,274 |
| Novo Nordisk | 20 | $580 |
| Boston Scientific | 7 | $487 |
| Lilly USA, LLC | 19 | $426 |
| Abbott | 9 | $402 |
| Amgen | 7 | $339 |
| Boehringer Ingelheim | 6 | $152 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Galderma Laboratories, L.p. | 2 | $116 |
| Merck | 1 | $101 |
| AbbVie | 1 | $100 |
| Lexicon Pharmaceuticals, Inc. | 1 | $96 |
| Mannkind Corporation | 3 | $82 |
| Esperion Therapeutics, Inc. | 1 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| GSK | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,487 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 20 | $18,738 |
| MounjaroTirzepatide | 17 | $17,348 |
| JardianceEmpagliflozin | 11 | $6,354 |
| Olanzapine | 16 | $221 |
| Gabapentin | 17 | $181 |
| Rosuvastatin Calcium | 28 | $159 |
| Metoprolol Succinate | 20 | $158 |
| Lisinopril | 21 | $129 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 32 | $128 |
| Atorvastatin Calcium | 33 | $95 |
| Fenofibrate | 11 | $91 |
| Meloxicam | 15 | $81 |
| Ibuprofen | 15 | $64 |
| Levothyroxine Sodium | 15 | $55 |
| Metformin Hcl | 23 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $580 | $18,73820 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $426 | $17,56933 claims |
| Boehringer IngelheimJardiance | $152 | $6,35411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Darin BrimhallLas Vegas$39.7M
- Alton WaltersLas Vegas$8.9M
- Michael JacobsLas Vegas$8.1M
- Nirupa PaulrajLas Vegas$5.8M
- Atoya AdamsLas Vegas$5.4M
- Roger EstevezLas Vegas$3.7M
- Syed PervaizLas Vegas$3.1M
- Vrijendra HoonLas Vegas$1.8M
- Robby Ann QuintosLas Vegas$1.4M
- Kent SwaineLas Vegas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.